multiplex IMMray PanCan-d assay

^[1]

Clinical significance

combines 8 serum biomarkers with CA19-9 to generate a risk score
specificity of 98% & sensitivity of 87% in identifying pancreatic ductal adenocarcinoma among patients at increased genetic or familial risk^[1]

↑ ^1.0 ^1.1 Hamza Z Assay Shows Ability to Detect Pancreatic Cancer in People at High Risk. Serum-based test showed specificity of 98% and sensitivity of 85% for ID'ing early-stage PDAC. MedPage Today February 18, 2022 https://www.medpagetoday.com/gastroenterology/pancreaticdiseases/97283
Brand RE, Persson J, Bratlie SO et al Detection of Early-Stage Pancreatic Ductal Adenocarcinoma from blood samples: Results of a multiplex biomarker signature validation study. Clin Transl Gastroenterol. 2022. February 14. PMID: https://www.ncbi.nlm.nih.gov/pubmed/35166713 https://journals.lww.com/ctg/Abstract/9900/Detection_of_Early_Stage_Pancreatic_Ductal.26.aspx